Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification

Abstract

Epigenetic suppression of appropriate Wnt negative feedback loops is selectively advantageous in LD tumours and differential <i>AXIN2</i> expression in LD/LI lesions can be exploited as a molecular biomarker. Distinguishing between LD/LI tumour types is important; patients with LD tumours retain sensitivity to Wnt ligand inhibition and may be stratified at diagnosis to clinical trials of Porcupine inhibitors.